Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05074160 · ClinicalTrials.gov registry record

OCS Liver Perfusion (OLP) Post-Approval Registry

A clinical trial of Liver Transplant, sponsored by TransMedics.

Active
Registry status
166
Enrollment target
9
Study locations

NCT05074160 is a study of Liver Transplant that is active but no longer recruiting, run by TransMedics. The registered enrollment target is 166 participants, below the 5,450-participant average among 19 other Liver Transplant trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05074160, a study of Liver Transplant, is active but no longer recruiting, sponsored by TransMedics.

ACTIVE NOT RECRUITING
Registry status
166 participants
Enrollment target
9
Study locations

Study Summary

The objective of the OLP Registry is to collect more data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to the approved indication and the OCS device performance in the real-world setting.

Conditions Studied

Interventions

  • DEVICE OCS Liver

Study Locations (9)

California

  • University of California San Diego - La Jolla
  • University of California San Francisco - San Francisco

Alabama

  • University of Alabama - Birmingham

Georgia

  • Emory - Atlanta

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Henry Ford Hospital - Detroit

Nebraska

  • University of Nebraska Medical Center - Omaha

North Carolina

  • Duke Medical Center - Durham

Texas

  • Houston Methodist - Houston

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2021-10-14
Est. Completion 2026-06

Sponsor

TransMedics

23 total trials

What the Registry Record Tells You About NCT05074160

The ClinicalTrials.gov registry entry for NCT05074160 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,450-participant average among 19 other Liver Transplant trials with a reported enrollment target (97% lower). The listed sponsor is TransMedics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Liver is the first listed.

NCT05074160 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Georgia.

Frequently Asked Questions

What is clinical trial NCT05074160 about?

NCT05074160 is a clinical study titled "OCS Liver Perfusion (OLP) Post-Approval Registry". The objective of the OLP Registry is to collect more data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to the approved indication and the OCS device performance in the real-world setting.

What is the current status of trial NCT05074160?

This trial is currently active not recruiting. The enrollment target is 166 participants. The study started on 2021-10-14. Estimated completion is 2026-06.

What conditions does trial NCT05074160 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT05074160?

The interventions under investigation include: OCS Liver (DEVICE).

Who is sponsoring clinical trial NCT05074160?

This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05074160 being conducted?

This trial has 9 study locations across Alabama, California, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.